drugset
drugset / Trial / NCT01055067

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

NCT01055067 ↗

Phase 2 Terminated 27 enrolled Daiichi Sankyo
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, single-arm study for safety and efficacy.

Timeline

Start
2010-02-02
Primary completion
2011-11-30
Completion
2011-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tivantinib Small molecule 360 mg —

Indications

germ cell tumor